In recent decades, there has been a substantial increase fungal infection (IFI), posing a significant threat to human health. Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus are the predominant pathogens responsible for the majority of IFIs in clinical settings. Despite advances in antifungal therapy, IFIs remain a major cause of morbidity and mortality, especially in immunocompromised and HIV-infected patients. The primary therapeutic families for fungal infections include polyenes, fluoropyrimidines, azoles, allylamines, and echinocandins. However, these antifungal...